CRISPR Therapeutics

CRISPR Therapeutics, headquartered in Zug, Switzerland, develops gene-editing medicines using CRISPR/Cas9 — a molecular tool that locates a specific DNA sequence and cuts it so the cell can repair or delete the targeted gene. With Vertex Pharmaceuticals, the company co-developed CASGEVY, the first approved CRISPR therapy, for sickle cell disease and beta thalassemia. The pipeline includes in vivo cardiovascular programs and CAR-T cell therapies for cancer and autoimmune disease.

Lead asset

CASGEVY · Approved · Sickle Cell Disease

cell therapy · CRISPR/Cas9 BCL11A enhancer edit

Pipeline

1 drug · 1 program

1 Oncology - Heme

Modalities

cell therapy×1